Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

55.26 -2.18 (-3.80%)
Delayed Quote Updated: 2:00 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
BMRN Q3 deep dive: pipeline expansion and order timing weigh on guidance
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) met Wall Street’s revenue expectations in Q3 2026, with sales up 32% year on year to $1.02 billion. On ... 
Via StockStory
News headline image
BioMarin (BMRN) Q3 2026 Earnings Call Transcript ↗
Revenue topped $1 billion for first time, fueled by Amicus integration. 
Via The Motley Fool
Topics Earnings
News headline image
BioMarin Pharmaceutical Q3 Earnings Call Highlights ↗
BioMarin Pharmaceutical (NASDAQ:BMRN) reported third-quarter revenue above $1 billion for the first time, driven by growth across its rare-disease portfolio and contributions from acquired Amicus... 
Via MarketBeat
Topics Earnings
BioMarin Pharmaceutical (NASDAQ:BMRN) Q3 EPS Beat, Revenue Miss, Soft Sales Outlook ↗
Via Chartmill
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) Screens as a Decent Value Stock on Cheap Forward Earnings ↗
Via Chartmill
BioMarin Pharmaceutical (NASDAQ:BMRN) Forms Tight Breakout Setup With Strong Technicals ↗
Via Chartmill
BioMarin (NASDAQ:BMRN) Stands Out as an Undervalued Stock with Solid Fundamentals ↗
Via Chartmill
BioMarin Pharmaceutical (NASDAQ:BMRN): A Value Stock with Strong Fundamentals ↗
Via Chartmill
News headline image
BioMarin Pharmaceutical (NASDAQ:BMRN) reports Q3 2026 in line with expectations but full-year sales guidance misses expectations
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) met Wall Street’s revenue expectations in Q3 2026, with revenue up 32% year on year to $1.02 billion. O... 
Via StockStory
News headline image
BioMarin Pharmaceutical (BMRN) Q3 earnings: what to expect
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be announcing earnings results tomorrow after market hours. Here’s what investors should know. Bio... 
Via StockStory
News headline image
3 Healthcare Stocks That Fall Short
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have... 
Via StockStory
News headline image
BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone ↗
BioMarin Pharmaceutical (NASDAQ:BMRN) said it is progressing with the integration of Amicus Therapeutics while pursuing additional business-development opportunities, as executives outlined growth... 
Via MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Presents a High-Quality Breakout Setup with Strong Technical Ratings ↗
Via Chartmill
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Shows Strong Value Potential with a 7/10 Overall Rating ↗
Via Chartmill
News headline image
3 Mid-Cap Stocks We Keep Off Our Radar
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco... 
Via StockStory
News headline image
3 Reasons to Avoid BMRN and 1 Stock to Buy Instead
BioMarin Pharmaceutical trades at $66.53 and has moved in lockstep with the market. Its shares have returned 9.3% over the last six months while the S&P 500 ... 
Via StockStory
Topics Stocks
News headline image
3 Value Stocks We Think Twice About
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ... 
Via StockStory
News headline image
Therapeutics Stocks Q2 Results: Benchmarking BioMarin Pharmaceutical (NASDAQ:BMRN)
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking a... 
Via StockStory
Topics Artificial Intelligence
News headline image
Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today
What Happened? Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 3.3% in the afternoon session after the company agreed to acquire Alest... 
Via StockStory
News headline image
3 Cash-Producing Stocks We Find Risky
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not... 
Via StockStory
News headline image
BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth ↗
BioMarin Pharmaceutical (NASDAQ:BMRN) outlined its growth strategy, integration plans for Amicus Therapeutics and pipeline priorities during a Canaccord discussion with Chief Financial Officer Brian... 
Via MarketBeat
News headline image
BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know
What Happened? Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 2.6% in the morning session after an analyst at Canaccord Genuity raise... 
Via StockStory
News headline image
BioMarin Pharmaceutical Q2 Earnings Call Highlights ↗
BioMarin Pharmaceutical (NASDAQ:BMRN) reported second-quarter 2026 revenue of nearly $1 billion, up 20% from a year earlier, as growth across its rare-disease portfolio and the recently completed... 
Via MarketBeat
Topics Earnings
News headline image
BioMarin Pharmaceutical (NASDAQ:BMRN) Delivers Impressive Q2 CY2026, Full-Year Outlook Slightly Exceeds Expectations
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 19.9% year on year ... 
Via StockStory
News headline image
BioMarin Pharmaceutical (BMRN) To Report Earnings Tomorrow: Here Is What To Expect
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results this Thursday after the bell. Here’s what investors should know. BioMarin Pha... 
Via StockStory
News headline image
1 Profitable Stock with Impressive Fundamentals and 2 We Turn Down
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
News headline image
2 Reasons to Avoid BMRN and 1 Stock to Buy Instead
BioMarin Pharmaceutical trades at $59.99 per share and has stayed right on track with the overall market, gaining 6.5% over the last six months. At the same ... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 of Wall Street’s Favorite Stocks with Competitive Advantages and 2 We Avoid
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember... 
Via StockStory
News headline image
2 Cash-Heavy Stocks with Exciting Potential and 1 We Ignore
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c... 
Via StockStory
News headline image
2 Healthcare Stocks for Long-Term Investors and 1 We Brush Off
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.